Sonendo, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
Sonendo, Inc. has entered into an amendment to its credit agreement, deferring and waiving certain amortization payments contingent upon successful equity financings.
OTC.Pink
Sonendo, Inc. announced a significant reduction in operating losses and free cash flow burn for the third quarter of 2024, despite a slight decrease in revenue.
OTC.Pink
Sonendo, Inc. was not the winning bidder in the bankruptcy auction for Biolase assets and will receive a break-up fee and expense reimbursement.
OTC.Pink
Sonendo, Inc. has executed a 1-for-200 reverse stock split, effective October 18, 2024, to consolidate its shares and potentially improve its stock price.
OTC.Pink
Sonendo reports preliminary Q3 2024 revenue between $7.9 and $8.0 million and increases its full-year 2024 revenue guidance.
OTC.Pink
Sonendo, Inc. has entered into an asset purchase agreement to acquire certain assets of Biolase, Inc. and its subsidiaries related to dental laser systems for $14 million in cash, assumption of liabilities, and the value of a pending litigation.
OTC.Pink
Sonendo, Inc. is considering a stalking horse bid for the assets of Biolase, Inc., which is potentially facing bankruptcy.
OTC.Pink
Sonendo Inc. reports the resignation of its Chief Talent Officer, Roy T. Chen, effective September 6, 2024, with the Human Resources function to be overseen by the CFO.
OTC.Pink
Sonendo, Inc. has dismissed Ernst & Young LLP and appointed BDO USA, P.C. as its new independent registered public accounting firm, effective August 14, 2024.
OTC.Pink
Sonendo Inc. reported improved financial results for the second quarter of 2024, including increased gross margins and a raised full-year revenue guidance.
OTC.Pink
Sonendo, Inc. held its annual meeting on June 10, 2024, where stockholders elected directors, ratified the accounting firm, and approved a reverse stock split.
OTC.Pink
Sonendo, a dental technology company, has appointed John Bostjancic as its new Chief Financial Officer, effective June 5, 2024, as part of a broader leadership restructuring.
OTC.Pink
Sonendo reported first quarter 2024 revenue of $7.0 million, exceeding prior guidance, and announced a strategic reset of its commercial and operational priorities.
OTC.Pink
Sonendo Inc. has withdrawn its appeal against delisting from the New York Stock Exchange, and its common stock is now trading on the OTCQX market.
OTC.Pink
Sadie Stern, a director at Sonendo, Inc., will not seek reelection at the 2024 Annual Meeting of Stockholders, concluding her service on the board and its committees.
OTC.Pink
Sonendo Inc. has amended the compensation package for its Interim Chief Financial Officer, Chris Guo, including a base salary, bonus eligibility, and a retention bonus.
OTC.Pink
Sonendo's full-year 2023 revenue grew by 5% to $43.9 million, while the company also divested its TDO software segment and restructured its debt.
OTC.Pink
Sonendo, Inc. has announced the resignation of its Chief Financial Officer, Michael P. Watts, effective March 15, 2024, and the appointment of Chris Guo as Interim CFO.
OTC.Pink
Sonendo divests its TDO Software business for $16 million and amends its credit agreement to include a $15 million principal repayment.
OTC.Pink
Karen McGinnis has resigned from Sonendo's Board of Directors and its Audit and Compensation Committees, effective March 31, 2024.